1 2 3 2 VOLUME 18 | NUMBER 8 | AUGUST 2012 nAture medicine Somatic mutant neural stem cells and NPCs are thought to be the source of HGAs, one of the most aggressive forms of tumors of the central nervous system (CNS) 1 . A very large fraction of individuals diagnosed with HGAs and glioblastomas (GBMs) are adults 2,3 . However, adult neurogenesis (that is, the presence and activity of NPCs in the postnatal and adult brain) is maintained at a high rate only during infancy and declines thereafter 4, 5 . Hence, the epidemiology of GBMs and the timing of adult neurogenesis are inversely correlated, and GBMs are often diagnosed several decades after the decline in brain stem cell activity. It has been previously found that endogenous and exogenous NPCs have a strong tropism for primary brain tumors and that NPCs can release tumor-suppressive factors 6-13 . However, the molecular nature of the factors that mediate cell death in HGA cells has not been elucidated. We show that NPCs induce tumor cell death through the release of endovanilloids. Endovanilloids 14 , such as arachidonoyl ethanolamide (AEA) and N-arachidonoyl dopamine (NADA), directly stimulate the vanilloid receptor, TRPV1, which is abundantly expressed on HGA 15 . TRPV1 is a nonselective cation channel that is best characterized in capsaicinsensitive sensory neurons of the dorsal root and trigeminal ganglia 16 . Synergistic TRPV1 activation by AEA in combination with other fatty acid ethanolamides, such as oleoyl ethanolamide (OEA) or palmitoyl ethanolamide (PEA), has previously been reported 15, 16 . The physiological role of the ion channel in non-neural tissues is largely unexplored 16 . Here we show that endovanilloid release from NPCs activates TRPV1 on HGA cells and thereby induces tumor-cell death.
Somatic mutant neural stem cells and NPCs are thought to be the source of HGAs, one of the most aggressive forms of tumors of the central nervous system (CNS) 1 . A very large fraction of individuals diagnosed with HGAs and glioblastomas (GBMs) are adults 2, 3 . However, adult neurogenesis (that is, the presence and activity of NPCs in the postnatal and adult brain) is maintained at a high rate only during infancy and declines thereafter 4, 5 . Hence, the epidemiology of GBMs and the timing of adult neurogenesis are inversely correlated, and GBMs are often diagnosed several decades after the decline in brain stem cell activity.
It has been previously found that endogenous and exogenous NPCs have a strong tropism for primary brain tumors and that NPCs can release tumor-suppressive factors [6] [7] [8] [9] [10] [11] [12] [13] . However, the molecular nature of the factors that mediate cell death in HGA cells has not been elucidated. We show that NPCs induce tumor cell death through the release of endovanilloids. Endovanilloids 14 , such as arachidonoyl ethanolamide (AEA) and N-arachidonoyl dopamine (NADA), directly stimulate the vanilloid receptor, TRPV1, which is abundantly expressed on HGA 15 . TRPV1 is a nonselective cation channel that is best characterized in capsaicinsensitive sensory neurons of the dorsal root and trigeminal ganglia 16 .
Synergistic TRPV1 activation by AEA in combination with other fatty acid ethanolamides, such as oleoyl ethanolamide (OEA) or palmitoyl ethanolamide (PEA), has previously been reported 15, 16 . The physiological role of the ion channel in non-neural tissues is largely unexplored 16 . Here we show that endovanilloid release from NPCs activates TRPV1 on HGA cells and thereby induces tumor-cell death.
RESULTS

NPCs induce HGA cell death through TRPV1
We investigated the signaling pathways that are activated in HGA cells after exposure to NPC-conditioned medium (NPC-CM). An analysis of gene expression changes (by microarrays of stimulated and control HGA cells; GSE37671) together with pharmacological studies using specific TRPV1 antagonists and molecular studies using specific TRPV1 knockdown in HGA cells suggested a role for NPC-derived endovanilloids as tumor suppressors. Furthermore, we observed by real time PCR that TRPV1 expression is positively correlated with grading in human primary brain tumors and that TRPV1 expression in tumors was higher than in human tumor-free brain (Supplementary Fig. 1a ).
We next explored the role of the endovanilloid system in NPCmediated HGA suppression in an established mouse model 8, 9, 17 . We orthotopically implanted brain tumor cells (DsRed-expressing GL261 cells) in nestin-GFP mice, which are a model for the visualization of NPCs 8, 18 (Fig. 1a) . Fourteen days after tumor cell injection, we found that subventricular NPCs migrated to HGAs that were located in the caudate putamen in these mice 8, 9, 17 . We identified NPCs using colocalization of GFP with established immunocytochemical markers, such as polysialylated neuronal cell adhesion molecule (PSA-NCAM) (Fig. 1b) or Musashi 8, 19, 20 . PSA-NCAM is also a marker of tumor-associated NPCs in humans (S.M., unpublished observations). Notably, we found that the mouse HGAs had higher amounts of immunolabeling for TRPV1 (Fig. 1c) than tumor-free brain, whereas only a small fraction of tumor-associated nestin-GFP + cells expressed TRPV1, and TRPV1 was absent from subventricular NPCs in the mice (Supplementary Fig. 1b) .
In a series of in vitro experiments, we found that stimulation of mouse HGAs with factors released from mouse NPCs (mNPC-CM), but not with factors released from their fully differentiated progeny (astrocytes, oligodendrocytes and neurons) or from fibroblasts (scrc), strongly reduced the viability of HGA cells over a timecourse of 3 d (Fig. 1d ; the data for the conditioned medium from the control cells were obtained on day 3). In subsequent experiments, we stimulated the mouse HGA cells for 3 d, unless indicated otherwise. Stimulation with mNPC-CM reduced the viability of the HGA cells by inducing cell death, as indicated by TUNEL and cytotoxicity assays (Supplementary Fig. 1c ). All cytotoxicity values are expressed as a percentage of the fully permeabilized cells (Supplementary Figs. 2 and 3) .
HGAs in the GL261 mouse glioma model express TRPV1 and contain specific binding sites for a selective TRPV1 ligand ( Supplementary Fig. 1d,e) . In this model, HGA cell death induced by stimulation with mNPC-CM was greatly reduced by blocking TRPV1 with the selective antagonists 16 iodoresiniferatoxin (I-RTX, 10 nM; Fig. 1e ) or capsazepine (CZP, 1 µM; Fig. 1e ) and by knockdown of TRPV1 (TRPV1-KD; Fig. 1e ). For the knockdown of TRPV1, we expressed five different TRPV1-directed shRNAs and control shRNA (scrambled) in GL261 cells and then selected for vectors that block TRPV1 function in GL261 cells. We subsequently quantified TRPV1 protein expression by quantitative proteomics (selected reaction monitoring, SRM) in knockdown and control GL261 cells (Supplementary Fig. 1d) . SRM allowed for a direct, specific and well-controlled quantification of TRPV1 protein expression. We verified the efficiency and specificity of the TRPV1 knockdown ( Supplementary Fig. 1d,e) by performing experiments with control shRNAs (scrambled shRNA) and with overexpression of a knockdown-resistant form of mouse TRPV1 (ref. 21 ) in TRPV1-KD HGA cells (Fig. 1e,f and Supplementary Fig. 2c ). Exposure to mNPC-CM strongly induced cell death in various HGA cell lines (Fig. 1f) and in three different primary human GBM cultures (Fig. 1g) , an effect that was blocked by the simultaneous application of either I-RTX (Supplementary Figs. 2b and 3a,b) or CZP. Notably, human NPC-CM also induced cell death in primary human GBMs after stimulation of TRPV1 (Fig. 1h) .
Overall, our cell-culture experiments showed that human and mouse NPCs release TRPV1 agonists, which induce HGA cell death. Our data from a mouse model showed that, in the young brain, many NPCs accumulate at HGAs. An analysis of TRPV1 expression in HGAs and tumor-free brain from mice and humans indicated that HGAs have high expression of TRPV1, whereas we found low TRPV1 expression in non-neoplastic CNS.
NPCs constitutively release endovanilloids
We quantified the concentrations of AEA, NADA, OEA, PEA and the endocannabinoid arachidonoyl glycerol (2-AG) in samples from mNPCs, fully differentiated progeny from mNPCs and mouse HGA cells. Differentiation of NPCs was achieved by growth factor withdrawal and transient addition of fetal bovine serum. After differentiation, we maintained the mNPC progeny in stem cell medium (as used for nondifferentiated mNPCs) and collected the conditioned media. The cell densities in the differentiated and undifferentiated NPCs were equivalent. Using mass-spectrometry, we found that mNPCs contained markedly high amounts of AEA, PEA and OEA, whereas the amounts of these endovanilloids in the differentiated mNPCs and the mouse HGA cells were much lower (Fig. 2a) . NADA was not detectable in any of the samples (data not shown). We found high concentrations of AEA in the mNPC-CM (Fig. 2b) , whereas the culture supernatants from the differentiated mNPCs or the HGA cells contained much less AEA, and the concentrations of other lipids were below the detection limit. We observed that the combined application of synthetic AEA, PEA and OEA exerts a cooperative effect on HGA cell death 22 , which was blocked by the addition of I-RTX (Fig. 2c) . The addition of fatty acid amide hydrolase (FAAH), which degrades ethanolamides 23 , fully abolished the effect of mNPC-CM ( Fig. 2d) and of human NPC-CM to induce cell death (data not shown).
We detected only low concentrations of the endocannabinoid 2-AG in mNPCs ( Fig. 2a; notably, 2-AG concentrations were higher in HGAs than in NPCs). Stimulation of HGAs with the vanilloid NADA induced cell death, and exposure of HGAs to mNPC-CM containing specific cannabinoid receptor antagonists did not blunt the HGA cell death (Supplementary Figs. 2f,g and 3c,d ). Together, these data suggest a role for endovanilloids (rather than endocannabinoids) as mediators of NPC-induced HGA cell death 22 . Next, we used FAAH-deficient (Faah -/-) mice, which have much higher amounts of endocannabinoids and endovanilloids in the CNS than wild-type mice 24 , as a brain tumor model. Faah -/-mice are an ideal model to elevate endogenous levels of fatty acid amides. However, the experiments with Faah -/-mice foreclosed any comparison to wildtype mice, because, for example, neural stem and immune cells have different activity in Faah -/-mice than wild-type mice. Thus, we investigated the effect of TRPV1 signaling on glioma growth by implanting TRPV1-KD or control HGAs into Faah -/-mice. We found that implantation of TRPV1-KD tumors resulted in much larger tumors than did implantation of control HGAs in these mice (Fig. 2e) . These data support our finding from the in vitro experiments and show that even greatly elevated concentrations of endogenous endocannabinoids and endovanilloids exert their tumor-suppressive effects exclusively through TRPV1 receptors in our glioma model. TRPV1 is abundantly expressed in dorsal root ganglion neurons (DRGs) 25 , and opening of the TRPV1 channel induces a cation influx, which can be measured, for example, as a rise in the intracellular concentration of free calcium ions. To assess the activity of endovanilloids released from NPCs, we designed a bioassay using DRGs from wild-type and Trpv1 -/-mice 26 . We stimulated the DRGs from both groups with mNPC-CM and measured the responses using Fura-2-based calcium imaging. We observed that 5.4% of the wildtype DRGs responded to both an initial stimulation with NPC-CM and to a subsequent stimulation with the selective TRPV1 agonist npg capsaicin. Only 0.85% of wild-type DRGs responded to initial stimulation with NPC-CM alone but not to the subsequent stimulation with capsaicin. In Trpv1 -/-mice, only 0.91% of the DRGs responded to mNPC-CM, which would suggest that TRPV1 is required for the majority of the responses to mNPC-CM observed in the wild-type DRG neurons (Supplementary Fig. 4a ). In addition, RT-PCR analysis of cultured mNPCs, their differentiated progeny and whole-brain extracts revealed that mNPCs express the major receptors and metabolic enzymes of the endovanilloid and endocannabinoid pathways (Supplementary Fig. 4b ). These data support the view that endovanilloids are major constituents of mNPC-CM and that endovanilloids are released from NPCs in physiologically relevant concentrations. Furthermore, mNPC-CM stimulated TRPV1-mediated Ca 2+ responses in primary human GBM cultures and in human, rat and mouse HGA cell lines (Fig. 2f and Supplementary Fig. 4c) . By performing pharmacological experiments and immunoelectron microscopy, we observed that TRPV1 in the GL261 HGAs was ectopically expressed in the endoplasmic reticulum (ER; Supplementary  Fig. 5b-e) . It has been previously described that TRPV1 in the ER has a lower sensitivity for capsaicin than TRPV1 located in the plasma membrane 16, 27 . We also found a lower sensitivity to capsaicin in our experiments (Supplementary Fig. 4c ).
TRPV1 induces cell death through ER stress
We next investigated the gene expression pattern in mouse tumor cells after incubation with nonconditioned medium (controls) or with mNPC-CM by microarrays (GSE37671). We found that ER stress genes, such as the activating transcription factor-3 gene (ATF3), were robustly upregulated in mouse HGA cells treated with mNPC-CM compared to controls. Immunocytochemical labeling and reporter gene assays in GL261 cells treated with mNPC-CM showed that the expression of ATF3 was higher in both the cytoplasm and nucleus of these cells than in controls and that mNPC-CM activates an ATF3-responsive element in a gene promoter (Fig. 3a,b) . Forced expression of ATF3 reduced the number of GL261 cells in culture and increased the number of TUNEL + tumor cells (Fig. 3c) . Notably, siRNA-mediated downregulation of ATF3 expression (Supplementary Fig. 6a ) in mouse HGA cells prevented the tumor cell death induced by mNPC-CM (Fig. 3d) . Therefore, ATF3 is necessary and sufficient for mediating the HGA cell death induced by mNPC-CM. Administering the TRPV1 antagonist CZP blocked the mNPC-CM-induced activation of the ATF3-dependent ER stress pathway in mouse HGAs (Supplementary Fig. 6b,c) . Supplementary Fig. 5 ) triggers the ATF3-dependent ER stress pathway in HGAs, which includes activation (phosphorylation, indicated by the P within a circle) of eukaryotic initiation factor 2 α (eiF2-α) and ATF4 (ref. 28 ; Supplementary Fig. 6 ). Increased expression of ATF3 is necessary and sufficient to mediate HGA cell death. All data are mean ± s.d. *P < 0.05, **P < 0.005, ***P < 0.001 by Student's t test.
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Electron microscopy revealed that GL261 cells treated with mNPC-CM had an enlarged ER as compared to controls (Fig. 4a  and Supplementary Fig. 6d ), which is a morphological hallmark of ER stress 28 . We quantified the effect of mNPC-CM (with or without the addition of CZP) on the ER in primary human GBM and in human, rat and mouse HGA cell lines using ER-tracker (Fig. 4b,c) . We then determined the effect of human NPC-CM on ER size in primary human GBMs (Fig. 4d) . In all HGA cells studied, we detected a very robust increase in ER size after stimulation with human or mouse NPC-CM, which was always attenuated by the addition of CZP (Fig. 4b-d and Supplementary Fig. 7) . Additionally, we used synthetic AEA and inducers of ER stress, such as tunicamycin or thapsigargin 29 , at concentrations that were below the threshold for ER stress induction when applied alone. We found that the simultaneous application of AEA and either tunicamycin or thapsigargin led to strong increases in ER size in GL261 cells (Fig. 4e) . The combined substances had a clear cooperative effect on the rise in ER size, confirming that vanilloid-induced signaling and ER stress are part of the same signal transduction pathway in HGA cells. These data show that human and mouse NPC-derived endovanilloids induce HGA cell death through the ER stress pathway (Fig. 4f) .
Age dependency of NPC-induced tumor suppression
To investigate whether NPC-derived endovanilloids can suppress HGAs in vivo, we performed orthotopic implantation of HGAs into nestin-GFP mice of different ages. Implantation of GL261 cells (TRPV1-KD or controls, which express a nontargeting shRNA) into young (30-day-old) mice resulted in the association of many endogenous NPCs to the tumor 8, 9, 17 (Fig. 5a) . Nestin-GFP + NPCs accumulated at GL261 control HGAs and TRPV1-KD HGAs in equal densities. Notably, we found that young mice injected with TRPV1-KD cells had significantly larger (70%) tumors compared to young mice injected with GL261 control cells (Fig. 5b) . We found no difference in tumor size in 90-day-old adult mice administered GL261 control cells and those administered TRPV1-KD cells (Fig. 5b) . In another set of experiments, we used a transgenic mouse model to manipulate the numbers of endogenous NPCs independently of aging. Therefore, we used cyclin D2 knockout (Ccnd2 -/-) mice, which have substantially lower amounts of adult neurogenesis than do wild-type mice 9, 30 . In these Ccnd2 -/-mice and their wild-type littermates, we orthotopically implanted GL261 cells (control or TRPV1-KD) and measured the tumor size 14 d after implantation. We found that the tumor size in the wild-type mice receiving control HGAs was at least 63% smaller than the tumors in the wild-type mice receiving TRPV1-KD tumor cells or Ccnd2 -/-mice receiving either control HGAs or TRPV1-KD tumor cells (Fig. 5c) . We then measured HGA cell death in vivo by systemically delivering propidium iodide (Fig. 5d) 31 . We noted that TRPV1-KD HGAs had much lower levels of HGA cell death than control HGAs.
In another set of experiments, we tested the effect of endovanilloids released from NPCs on the overall survival of a cohort of wildtype mice with HGAs. First, we orthotopically implanted control or TRPV1-KD GL261 cells into young mice and compared the cumulative survival times of the two groups. We observed that young wildtype tumor-bearing mice (Fig. 5e) had a significantly longer survival time after implantation than the older mice. However, when we Mice implanted at P30 outlive mice implanted at P90, unless the mice implanted at P30 were given TRPV1-KD tumor cells (n ≥ 10 mice per group, male and female; e). Implantation of P90 mice with both NPCs and control HGAs (scrambled) improves survival but co-injection of NPCs with TRPV1-KD HGAs does not (n ≥ 6 mice per group, male and female; f). All data are mean ± s.d. *P < 0.05, **P < 0.005, ***P < 0.001, NS, not significant by Student's t test. In e and f, survival was statistically significantly different, with P < 0.001: in e, this comparison was between the 'P30, GL261-scrambled' or 'P30, GL261-rescue' group and all other groups, and in f, this comparison was between the 'P90, GL261-scrambled + NPCs' group and all other groups.
npg implanted young mice with TRPV1-KD HGA cells they survived, on average, the same amount of time as older mice. These data show that younger mice have an intrinsic protective mechanism against HGAs that is dependent on endovanilloid signaling. In a second study, we investigated whether the survival-promoting effect that we observed could be attributed specifically to NPCs. Therefore, we implanted adult mice with exogenously cultivated NPCs and control HGAs or TRPV1-KD tumor cells (Fig. 5f ). We found that implantation of control HGAs always generated tumors but that co-implantation of mNPCs together with HGAs prolonged survival ( Fig. 5e,f ; P < 0.001).
We also found that the survival-promoting effect of NPCs in adult mice was absent after implantation with TRPV1-KD cells (Fig. 5f ). Our data suggest that NPCs release endovanilloids in vivo in a way similar to NPCs in vitro. Consistently, the extent of the NPC-mediated antitumor response depended on the amount of adult neurogenesis.
Synthetic vanilloids as therapeutics for HGAs
We next investigated the therapeutic potential of the synthetic, nonpungent, blood-brain-barrier-permeable vanilloid arvanil 32, 33 . We allowed control HGAs to develop for 5 d in organotypic brain slice cultures obtained from wild-type mice. The addition of temozolomide 34 (200 µM, which is the current standard of care for the treatment of patients with GBM) or arvanil (50 nM) strongly reduced the size of the HGAs as compared to vehicle-treated controls (Fig. 6a,b) . Furthermore, arvanil induced a TRPV1-dependent Ca 2+ signal and TRPV1-dependent cell death in the HGAs (Supplementary Fig. 8) .
In further experiments, we orthotopically implanted TRPV1-KD or control HGAs into wild-type mice and treated both groups with arvanil as described above. We compared the survival of these arvanil-treated mice to a cohort of mice receiving control HGA cells and no arvanil treatment. We found that the mice receiving the control HGAs plus arvanil had significantly longer survival time than the mice receiving TRPV1-KD tumor cells plus arvanil ( Fig. 6c ; P < 0.001) or control tumors without arvanil. These data indicate that arvanil elicits its therapeutic effect as a TRPV1 agonist. To determine whether arvanil would also lead to longer survival in other HGA models, we implanted primary human GBM cells (GBM1 and GBM2) into severe combined immunodeficient (SCID) mice. At 1 week after implantation, we examined the tumor development in the mice and administered arvanil (a total of four intraperitoneal injections of 1 mg kg -1 body weight each) or vehicle. Treatment with arvanil substantially prolonged survival as compared to treatment with vehicle ( Fig. 6d-f ; P < 0.001). We then compared the effects of the application of arvanil and temozolomide (alone and in combination) on survival after implantation of a third primary human HGA culture (GBM3) in immune deficient (SCID) mice. We found that arvanil prolonged survival in a cohort of SCID mice that received GBM3 cells that did not respond to temozolomide (given once daily for 5 d at 100 mg kg −1 body weight (ref. 35); Fig. 6f ; P < 0.001). These data show the potential clinical value of an experimental HGA therapy using vanilloids, which may also offer a new therapeutic option for temozolomide-resistant HGAs 36 .
DISCUSSION
We have shown that HGAs have high expression of TRPV1 and that TRPV1 stimulation induces tumor cell death. Neural stem and precursor cells home in on HGAs and release antitumorigenic TRPV1 agonists (endovanilloids). Endogenous and exogenous NPCs show extensive tropism for brain tumors [6] [7] [8] [9] [10] . However, the number of endogenous NPCs accumulating at HGAs depends on the proliferative activity in the stem cell niche and declines before the onset of adulthood 9 . Hence, the recruitment of large numbers of NPCs to a tumor, and the concomitant antitumorigenic release of endovanilloids, is mostly restricted to the young brain. Additionally, other agerelated changes in neural stem cell physiology may also impinge on the ability of NPCs to suppress tumors 37, 38 .
We show here that NPCs are a primary source of endogenous TRPV1 and cannabinoid receptor agonists such as AEA 15, 39 . This finding was supported by our detection of high amounts of AEA and related acylethanolamides in undifferentiated NPCs, as well as our findings that factors released by NPCs evoke TRPV1-dependent Ca 2+ responses in DRGs and HGAs, that the tumor-suppressive effect of NPC-CM is lost after the addition of FAAH and that NPC-induced HGA cell death is dependent on TRPV1 in vitro and in vivo. These data are in agreement with previous reports indicating that synthetic AEA induces HGA cell death 40 .
A role for TRP channels in tumor suppression was previously suggested by us and others [41] [42] [43] [44] [45] , but the present study is the first, to our knowledge, to identify NPCs as a cellular source for tumor-suppressive endovanilloids and uncover the role of TRPV1 agonists and modulators released by NPCs on HGA cell death. Overall, our study suggests that endovanilloids are intrinsic tumor suppressors in the brain and that synthetic vanilloid compounds may have clinical potential for the treatment of brain tumors.
METHODS
Methods and any associated references are available in the online version of the paper.
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